Last reviewed 2026-05-23 · How we verify

Rapimelt

AstraZeneca · Phase 1 active Small molecule ✓ Verified May 2026

Rapimelt is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development. Also known as: ZOMIG®.

Rapimelt, also known as Zolmitriptan, is a medication studied for its potential to treat Migraine. It works by occupying the 5-HT1B receptor in the brain, as determined by a PET study using the compound [11C]AZ10419369.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Rapimelt
Also known as	ZOMIG®
Sponsor	AstraZeneca
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rapimelt CI brief — competitive landscape report
Rapimelt updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about Rapimelt

What is Rapimelt?

Rapimelt is a Small molecule drug developed by AstraZeneca.

Who makes Rapimelt?

Rapimelt is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Rapimelt also known as anything else?

Rapimelt is also known as ZOMIG®.

What development phase is Rapimelt in?

Rapimelt is in Phase 1.

Manufacturer: AstraZeneca — full pipeline
Therapeutic area: All drugs in Other
Also known as: ZOMIG®

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing